Market Overview:

Neurofibromatosis type 1 (NF1) is a rare disease characterized by changes in skin color (pigmentation) and growth of tumors in cutaneous nerves and other parts of the body. The signs and symptoms of this disease vary greatly among those affected. In children, NF1 presents with multiple patches of skin surrounded by dark pigmentation, which may enlarge and form freckles in the armpits, while in adults, they develop into non-cancerous tumors in the spinal cord or along the nerves of the patient’s body. There is no cure for neurofibromatosis, but the signs and symptoms can be managed. Generally, the sooner a person is seen by a physician trained in the treatment of neurofibromatosis, the better the outcome.

Get Sample PDF Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/4149

Competitive Landscape:

Major players operating in the global Neurofibromatosis Type 1 Market are Healx, AstraZeneca PLC, Merck & Co., Inc, Pharm Tech Corporation, and NFlection Therapeutics, among others.

Key Market Drivers:

Rising neurofibromatosis type 1 cases globally are expected to propel the neurofibromatosis type 1 market growth over the forecast period. For example, according to the National Cancer Institute, since NF1 is relatively rare, approximately 1 in 2,500 to 3,000 people are believed to be living with the disease, a hospital or clinic is unlikely to encounter more than a handful of people with NF1.

Additionally, the growing demand for a safe and effective treatment for NF1 is expected to accelerate the growth of the neurofibromatosis type 1 market. For example, in June 2020, AstraZeneca announced that selumetinib had been granted Orphan Drug Designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1). The Japanese Ministry of Health, Labor and Welfare grants the SDG to drugs for the treatment of diseases that affect fewer than 50,000 patients in Japan and for which there is significant unmet medical need.

COVID-19 impact analysis:

Many people with neurofibromatosis wonder if their diagnosis of NF puts them at high risk for side effects from the COVID-19 vaccine. However, there is no evidence of specific safety issues with the COVID-19 vaccine in people with NF. According to the Centers for Disease Control and Prevention (CDC), such medical conditions can put people at high risk of serious illness from COVID-19. Thus, it is important to minimize possible exposure and follow safety guidelines.

Key points to remember:

  • The neurofibromatosis type 1 market is expected to grow at a CAGR of 11.3% during the forecast period owing to frequent new drug approvals and launches in the market. For example, in April 2020, AstraZeneca and Merck & Co. announced that the United States Food and Drug Administration (FDA) had approved the kinase inhibitor Koselugo (selumetinib) for the treatment of pediatric patients two years of age and older. with neurofibromatosis type 1 (NF1) who have symptomatic and inoperable plexiform neurofibromas (PN).
  • Among regions, North America, Europe, and Asia-Pacific are expected to experience robust growth in neurofibromatosis type 1 market owing to rising demand for safe and effective treatments, rise in cases of neurofibromatosis type 1 and the emphasis placed on research and development. , and frequent new drug approvals and launches in these regions.

For example, in June 2020, Nflection Therapeutics received US$20 million in funding from Venbio Partners and F-prime Capitals. The company also announced the launch of the first clinical trial of its flagship product, NFX-179 Gel, a topical therapy. The phase 2a study will focus on the safety, tolerability and pharmacokinetic/pharmacodynamic study of NFX-179 gel in adult patients with cutaneous NF1.

Reasons to Buy this Neurofibromatosis Type 1 Market Report

➡ Save time carrying out entry-level research by identifying the size, growth and key players in the emerging Neurofibromatosis Type 1 Market

➡Use Five Forces Analysis to determine the competitive intensity and hence the attractiveness of the emerging Neurofibromatosis Type 1 Market

➡Key Company Profiles Reveal Details of Major Neurofibromatosis Type 1 Market Players Emerging Five Operations and Financial Performance

➡Add weight to presentations and presentations by understanding the future growth prospects of the emerging Neurofibromatosis Type 1 Market with a five-year historical forecast

➡Compares data from North America, South America, Asia-Pacific, Europe and the Middle East, as well as individual chapters on each region.

Buy this report directly with a fixed discount of 2000 USD @ https://www.coherentmarketinsights.com/promo/buynow/4149

Contents

Chapter 1 Industry overview
1.1 Definition
1.2 Assumptions
1.3 Scope of research
1.4 Market Analysis by Regions
1.5 Neurofibromatosis Type 1 Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Neurofibromatosis Type 1 Industry Impact

Chapter 2 Global Neurofibromatosis Type 1 Competition by Types, Applications, and Top Regions and Countries
2.1 Global Neurofibromatosis Type 1 (Volume and Value) by Type
2.3 Global Neurofibromatosis Type 1 (Volume and Value) by Regions

chapter 3 Generation market analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Neurofibromatosis Type 1 Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Neurofibromatosis Type 1 Market Analysis
Chapter 6 Analysis of the Neurofibromatosis Type 1 Market in East Asia
Chapter 7 Analysis of the neurofibromatosis type 1 market in Europe
Chapter 8 South Asia Neurofibromatosis Type 1 Market Analysis
Chapter 9 Southeast Asia Neurofibromatosis Type 1 Market Analysis
Chapter 10 Middle East Neurofibromatosis Type 1 Market Analysis
Chapter 11 Market Analysis of Neurofibromatosis Type 1 in Africa
Chapter 12 Oceania Neurofibromatosis Type 1 Market Analysis
Chapter 13 South America Neurofibromatosis Type 1 Market Analysis
Chapter 14 Company profiles and key figures of the neurofibromatosis type 1 industry
Chapter 15 Global Neurofibromatosis Type 1 Market Forecast (2021-2027)
Chapter 16 conclusion
Research Methodology

Request a PDF brochure here @ https://www.coherentmarketinsights.com/insight/request-pdf/4149

About Us:

Coherent Market Insights is a global market intelligence and advisory organization that provides syndicated research reports, custom research reports and advisory services. We’re known for our actionable insights and genuine reports in a variety of fields, including aerospace and defense, agriculture, food and beverage, automotive, chemicals and materials, and virtually any field and an exhaustive list of subdomains under the sun. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leading role in providing insight in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.

Contact:

Consistent market information
1001 4th Ave, #3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837